Two years' experience with denosumab for children with osteogenesis imperfecta type VI
about
Recent developments in osteogenesis imperfectaSclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.Osteogenesis imperfecta: pathophysiology and treatment.Optimizing Bone Health in Duchenne Muscular Dystrophy.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.Bone Material Properties in Osteogenesis Imperfecta.Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.Pediatric Osteoporosis: Diagnosis and Treatment Considerations.Pharmacological and biological therapeutic strategies for osteogenesis imperfecta.Osteoporosis in Children with Chronic Illnesses: Diagnosis, Monitoring, and Treatment.Long-term follow-up in osteogenesis imperfecta type VI.Monoclonal antibodies for treating osteoporosis.Developments in rare bone diseases and mineral disorders.Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings.Osteogenesis imperfecta and therapeutics.Emerging targeted drug therapies in skeletal dysplasias.Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI.
P2860
Q26781674-0F42729E-51CD-45A3-A21A-720CF3BE2539Q36889245-53333FEF-B564-4CB6-A0A4-336A33E5679AQ37384560-D9626B64-07B1-4FB9-83ED-3F8C10BF24EDQ38521472-59B140A4-2848-4F61-8004-2769765DA8EBQ38540530-58D64A01-2EFD-48A4-9023-6353B9952624Q38712724-4562F006-5003-42F3-BF3C-E1ACFF7AD5F5Q38778771-9FC05C61-BC36-4A9C-B6EB-06E858F1FE6CQ38918970-782CD07E-12D1-4015-8222-AA2B82EC4A81Q38921958-2CE373AD-DCB3-4CA8-A026-D67A27F8CBDCQ38998578-F938B066-CAA6-4073-B952-EB6F5DAB3AEDQ39377609-2ED44287-0963-4718-BA04-99774DE6D34EQ39423436-A1DD7204-C8CF-49B2-B9FC-C058D4B9D887Q47638169-1A201AA9-C20C-4145-BE12-1F3682718CF3Q49413973-4428BAED-AEA7-4BDA-9456-2D869DE7233CQ49884599-4D49327F-B47C-44AC-95E4-F15035E288A7Q52655586-3E4DD263-1AAE-446C-BF71-F23578296FE7Q54715218-1FA73537-4BEB-4019-883D-81590A4E1EECQ54990084-04B4BFB6-EF01-4851-9C14-EFF444241734
P2860
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@ast
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@en
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@nl
type
label
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@ast
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@en
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@nl
prefLabel
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@ast
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@en
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@nl
P2093
P2860
P1476
Two years' experience with denosumab for children with osteogenesis imperfecta type VI
@en
P2093
Christian Netzer
Eckhard Schoenau
Friederike Koerber
Heike Hoyer-Kuhn
P2860
P2888
P356
10.1186/S13023-014-0145-1
P577
2014-09-26T00:00:00Z
P5875
P6179
1000848897